Healthcare Professionals - Frequently Asked Questions

How many hours after the injury should the injection of SportVis™ be made? What is the earliest and latest point of intervention?

The injection is best performed within the first 48 hours because of it is at that point that the maximum fibrin is present but it can be given anytime up to about the 8th day post injury if there are still symptoms. It can be given soon after the injury once it is properly assessed and stabilised (i.e. within 2 hours of the injury).

Why is the treatment 2 injections with a 2-3 day time interval between?

Optimal results were seen after 2 injections. The 2-3 days interval before injection number 2 is intended to give the injury time to respond to the first injection, providing optimal pain relief and continued reduction in tissue damage.

Is it possible to inject immediately the injury happens, for example during a sporting contest?

If the conditions are adequate for an injection, it can be done on the sideline within minutes of the injury. Pain relief is usually very rapid according to various case studies and anecdotal reports. The earliest injection after injury during the clinical trial of SportVis™ was about one hour.

Can SportVis™ be injected if the patient has a haematoma due to the acute ankle sprain?

Injection into a haematoma shoudn’t be performed. A proper assessment of the injury is vital.

Is SportVis™ listed on the doping list – that is, can I use it on my elite athletes?

SportVis™ is not listed as a doping agent and can be used on athletes of all standards.

Could you specify the place and way of injection?

•  Injury site is first located and assessed.
•  Injection is done with 1 puncture and in 3 phases using anatomical landmarks.
•  Locate the area of greatest tenderness – usually anterior to lateral malleolus (sometimes at distal TFL site)
•  Inject SportVis™ into the most painful area anterior to the CFL using the fanning technique proximally (fibular insertion) to distally (calcaneal insertion) along the lateral malleolus.
•  A third of each SportVis™ syringe is released into the injury site during withdrawal of the syringe during each of the 3 phases. At the end of the injection process, the syringe should be empty.
•  In the event of injury to another ligament, another separate syringe of SportVis™ may be administered.
TFL: Talofibular ligament
CFL: Calcaneo fibular ligament

Why is the fanning technique recommended for SportVis™ injection?

The fanning technique is key to the optimal administration of SportVis™ as it ensures a physical distribution of SportVis™ which allows larger surface area coverage of the soft tissue for maximum repair. More information on the fanning technique can be provided on request - including access to a training video.

How does SportVis™ work?

SportVis™’s main ingredient is STABHA™ (Soft Tissue Adapted Biocompatible Hyaluronic Acid).

During the first phase of healing, inflammation at the injury site results in the generation of a fibrin matrix. Due to its high biocompatibility with the soft tissue, SportVis™ interacts with the fibrin matrix. Moreover SportVis™ helps to limit inflammation, optimise recovery and relieve pain at the injury site.
SportVis™ is believed to increase the quality of healing by reducing scar tissue formation.
SportVis™ is an effective and efficient method of quantitative and qualitative management of ankle sprains and reduces the time to recovery.

Should SportVis™ replace R.I.C.E. as standard of care?

SportVis™ was not created to replace R.I.C.E.. It is advised that SportVis™ and R.I.C.E. should be used concomitantly.

What is the manufacturing process of SportVis™?

SportVis™ is produced by an innovative manufacturing process which is patented. SportVis™ is derived from continuous fermentation of Streptococcus equi.
After fermentation, the biomass is separated from the solution by filtration to obtain a cell-free solution. This solution is then purified by diafiltration to remove low molecular weight impurities (those derived from the production organism’s metabolism, the residual components of the nutrient medium). The precipitation of nucleic acids and endotoxins is obtained by the addition of a cationic surfactant.
This results in a purity profile that allows SportVis™ to be biocompatible with soft tissues.

What is the molecular weight of SportVis™?

Molecular weight is not the focal point of SportVis™. SportVis™ was developed using a very carefully selected set of parameters to enable optimal rheological properties, thus impacting residence time in the soft tissue.

Purity is a key factor rather than molecular weight. Both the purity profile and ideal residence time in the soft tissue enable SportVis™ to achieve maximum interaction with the torn ligament.

Can SportVis™ be co-administered with other medicines like corticosteroids at injection?

No studies are available on mixing SportVis™ with other medicines. Therefore this would be dependent on the judgement and responsibility of the Healthcare professional.

Why is the SportVis™ syringe volume 1.2 ml?

To enable appropriate delivery of the optimal concentration of STABHA™ without delivering a volume that would cause excess pressure and pain at the injury site.